Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
Background: MLC601 is a possible modulator of amyloid precursor protein processing, and in a clinical trial study MLC601 showed some effectiveness in cognitive function in Alzheimer's disease (AD) patients. We aimed to evaluate the effectiveness and safety of MLC601 in the treatment of mild to...
Main Authors: | Hossein Pakdaman, Ali Amini Harandi, Hamidreza Hatamian, Mojgan Tabatabae, Hosein Delavar Kasmaei, Amirhossein Ghassemi, Koroush Gharagozli, Farzad Ashrafi, Pardis Emami Naeini, Mehrnaz Tavakolian, Darush Shahin |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2015-03-01
|
Series: | Dementia and Geriatric Cognitive Disorders Extra |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/375295 |
Similar Items
-
MLC601 in vascular dementia: an efficacy and safety pilot study
by: Pakdaman H, et al.
Published: (2017-10-01) -
Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study
by: Hossein Pakdaman, et al.
Published: (2018-04-01) -
Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study
by: Hossein Pakdaman, et al.
Published: (2017-05-01) -
Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
by: O'Regan, Jordana
Published: (2014) -
Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
by: O'Regan, Jordana
Published: (2014)